• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

ACS Chem Biol . SARS-CoV-2 Spike N-Terminal Domain Engages 9- O-Acetylated α2-8-Linked Sialic Acids

tetano

Editor, Senior Moderator
ACS Chem Biol


. 2023 Apr 27.
doi: 10.1021/acschembio.3c00066. Online ahead of print. SARS-CoV-2 Spike N-Terminal Domain Engages 9- O-Acetylated α2-8-Linked Sialic Acids

Ilhan Tomris[SUP] 1 [/SUP], Luca Unione[SUP] 2 3 [/SUP], Linh Nguyen[SUP] 4 [/SUP], Pouya Zaree[SUP] 1 [/SUP], Kim M Bouwman[SUP] 1 [/SUP], Lin Liu[SUP] 5 [/SUP], Zeshi Li[SUP] 1 [/SUP], Jelle A Fok[SUP] 1 [/SUP], María Ríos Carrasco[SUP] 1 [/SUP], Roosmarijn van der Woude[SUP] 1 [/SUP], Anne L M Kimpel[SUP] 1 [/SUP], Mirte W Linthorst[SUP] 1 [/SUP], Sinan E Kilavuzoglu[SUP] 1 [/SUP], Enrico C J M Verpalen[SUP] 1 [/SUP], Tom G Caniels[SUP] 6 7 [/SUP], Rogier W Sanders[SUP] 6 7 8 [/SUP], Balthasar A Heesters[SUP] 1 [/SUP], Roland J Pieters[SUP] 1 [/SUP], Jesús Jiménez-Barbero[SUP] 2 8 9 10 [/SUP], John S Klassen[SUP] 4 [/SUP], Geert-Jan Boons[SUP] 1 5 [/SUP], Robert P de Vries[SUP] 1 [/SUP]



Affiliations
Abstract

SARS-CoV-2 viruses engage ACE2 as a functional receptor with their spike protein. The S1 domain of the spike protein contains a C-terminal receptor binding domain (RBD) and an N-terminal domain (NTD). The NTD of other coronaviruses includes a glycan binding cleft. However, for the SARS-CoV-2 NTD, protein-glycan binding was only observed weakly for sialic acids with highly sensitive methods. Amino acid changes in the NTD of variants of concern (VoC) show antigenic pressure, which can be an indication of NTD-mediated receptor binding. Trimeric NTD proteins of SARS-CoV-2, alpha, beta, delta, and omicron did not reveal a receptor binding capability. Unexpectedly, the SARS-CoV-2 beta subvariant strain (501Y.V2-1) NTD binding to Vero E6 cells was sensitive to sialidase pretreatment. Glycan microarray analyses identified a putative 9-O-acetylated sialic acid as a ligand, which was confirmed by catch-and-release ESI-MS, STD-NMR analyses, and a graphene-based electrochemical sensor. The beta (501Y.V2-1) variant attained an enhanced glycan binding modality in the NTD with specificity toward 9-O-acetylated structures, suggesting a dual-receptor functionality of the SARS-CoV-2 S1 domain, which was quickly selected against. These results indicate that SARS-CoV-2 can probe additional evolutionary space, allowing binding to glycan receptors on the surface of target cells.


 
Back
Top Bottom